Uremia in general and peritoneal dialysis in particular bring with them risk factors for the development of cardiovascular disease. These factors include multiple lipid abnormalities, hyperhomocysteinemia, abdominal obesity, chronic inflammation, hypoalbuminemia, oxidative stress, and AGE formation. When these are combined with conventional risk factors, one can appreciate why the incidence of cardiovascular disease is so high in peritoneal dialysis patients. Treatment strategies should address each of these risks appropriately.
RaineA.E.G., for The European Dialysis Transplant Association Registry Committee. Combined report on regular dialysis and transplantation in Europe, XXII, 1991.Nephrol Dial Transplant.1992; 2: 7–35.
2.
United States Department of Health and Human Services, Public Health Servic, National Institutes ofHealth.Survival probabilities and causes of death. In: USRDS Annual Data Report, 1991.Bethesda, MD: U.S. Renal Data System; 1991: 31–40.
BloembergenW.E., PortF.K., MaugerE.A., WolfeR.A.A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis.J Am Soc Nephrol.1995; 6: 177–83.
5.
BloembergenW.E., PortF.K., MaugerE.A., WolfeR.A.A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis.J Am Soc Nephrol.1995; 6: 184–91.
6.
ParfreyP.S., HarnettJ.D., GriffithsS.M., TaylorR., BarréP.The clinical course of left ventricular hypertrophy in dialysis patients.Nephron.1990; 55: 114–20.
7.
SilberbergJ.S., BarréP., PrichardS., SnidermanA.D.Left ventricular hypertrophy: An independent determinant of survival in end stage renal disease.Kidney Int.1989; 36: 286–90.
West of Scotland Coronary Prevention Study Group. Influence of Pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSC OPS).Circulation.1998; 97: 1440–5.
10.
SacksF.M., PfefferM.A., MoyeL.A., RouleauJ.L., RutherfordJ.D., ColeT.The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.N Engl J Med.1996; 335: 1001–9.
LamarcheB., TchernofA., MoorjaniS., CantinB., DagenaisG.R., LupienP.J.Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study.Circulation.1997; 95: 69–75.
13.
SnidermanA.D., CianfloneK., KwiterovichPOJr., HutchinsonT., BarreP., PrichardS.Hyperapobetalipoproteinemia: The major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis.Atherosclerosis.1987; 65: 257–64.
14.
PrichardS., CianfloneK., SnidermanA.The role of the liver in the pathogenesis of hyperlipidemia in patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis.Perit Dial Int.1996; 16(Suppl 1): S207–10.
15.
MisraM., ReaveleyD.A., AshworthJ., MullerB., SeedM., BrownE.D.Six- month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis.Perit Dial Int.1997; 17: 279–86.
16.
JeppesenJ., HeinH.O., SuadicaniP., GyntelbergF.Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study.Circulation.1998; 97: 1029–36.
17.
RosengrenA., WihelmsenL., ErikssonE., RisbergB., WedelH.Lipoprotein (a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men.BMJ.1990; 301: 1248–51.
18.
KronenbergF., KönigP., NeyerU., AuingerM., PrisbasnigA., LangU., ReitingerJ., PinterG.Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.J Am Soc Nephrol.1995; 6: 110–20.
KawaguchiY., KuboH., YamamotoH., N akayamaM., YokoyamaK., ShigematsuT.Is atherosclerosis accelerated by CAPD?Perit Dial Int.1996; 16(Suppl 1): S223–30.
23.
KangD.H., YoonK.I., LeeS.W., KangS.W., ChoiK.H., LeeH.Y.Impact of nutritional status on serum lipoprotein(a) concentration in patients undergoing continuous ambulatory peritoneal dialysis.Perit Dial Int.1996; 16(Suppl 1): S241–5.
24.
KochM., KutkuhnB., TrenkwalderE., BachD., GrabenseeB., DieplingerH.Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients.J Am Soc Nephrol.1997; 8: 1889–98.
25.
StenvinkelP., HeimbürgerO., TuckC.H., BerglundL.Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure.Kidney Int.1998; 53: 1336–42.
26.
ClarkeR., DalyL., RobinsonK., NaughtenE., CahalaneS., FowlerB.Hyperhomocysteinemia: An independent risk factor for vascular disease.N Engl J Med.1991; 324: 1149–55.
27.
NygardO., NordrehaugJ.E., RefsumH., UelandP.M., FarstadM., VollsetS.E.Plasma homocysteine levels and mortality in patients with coronary artery disease.N Engl J Med.1997; 337: 230–6.
28.
BachmannJ., TepelM., RaidtH., RiezlerR., GraefeU., LangerK.Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients.J Am Soc Nephrol.1995; 6: 121–5.
29.
DennisV.W., RobinsonK.Homocysteinemia and vascular disease in end-stage renal disease.Kidney Int.1996; 50: S11–17.
30.
BostomA.G., LathropL.Hyperhomocysteinemia in endstage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes.Kidney Int.1997; 52: 10–20.
31.
MoustaphaA., NasoA., NahlawiM., GuptaA., ArheartK.L., JacobsenD.W.Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.Circulation.1998; 97: 138–41.
32.
RobinsonK., ArheartK., RefsumH., BrattstromL., BoersG., UelandP., etal, for the European COMAC group. Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease.Circulation.1998; 97: 437–43.
33.
BostomA.G., LathropL.Hyperhomocysteinemia in endstage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes.Kidney Int.1997; 52: 10–20.
34.
BostomA.G., SheminD., LapaneK.L., HumeA.L., YoburnD., NadeauM.R.High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients.Kidney Int.1996; 46: 147–52.
35.
MydlikM., DerziovaK., ZemberovaE.Metabolism of vitamin B6 and its requirement in chronic renal failure.Kidney Int.1997; 52(Suppl 6): S56–9.
36.
van GuldenerC., JanssenMJFM, LambertJ., ter WeeP.M., DonkerA.J.M., StehouwerC.D.A.Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after longterm therapy.Perit Dial Int.1998; 18: 282–9.
37.
HoldtB., KortenG., KnippelM., LehmannJ.K., ClausR., HoltzM.Increased serum level of total homocysteine in CAPD patients despite fish oil therapy.Perit Dial Int.1996; 16(Suppl 1): S246–9.
38.
DesprésJ.P., LamarchB., MauriegeP., CantinB., DagenaisG., MoorjaniS.Hyperinsulinemia as an independent risk factor for ischemic heart disease.N Engl J Med.1996; 334: 952–7.
39.
GaudetD., VohlM.C., PerronP., TremblayG., GagnéC., LesiègeD.Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene.Circulation.1998; 97: 871–7.
40.
FliserP., PaciniG., EngelleiterR., Kautzky -WillerA., PragerR., FranekR.Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease.Kidney Int.1998; 33: 1343–7.
41.
FernströmA., HylanderB., MoritzA., JacobssonH., RössnerS.Increase of intra-abdominal fat in patients treated with CAPD.Perit Dial Int.1998; 18: 166–71.
42.
BreborowiczA., OreopoulosD.G.Evidence for the presence of chronic inflammation during peritoneal dialysis: Therapeutic implications.Perit Dial Int.1997; 17(Suppl 2): S37–41.
43.
RidkerP.M., GlynnR.J., HennekensC.H.C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.Circulation.1998; 97: 2007–11.
44.
WannerC., ZimmermanJ., QuaschningT., GalleJ.Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients.Kidney Int.1997; 52(Suppl 62): S53–5.
45.
HelnrichJ., SchulteH., SchonfeldR., KohlerE., AssmannG.Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.Thromb Haemost.1995; 73: 374–9.
46.
KimK.J., YangW.S., KimS.B., LeeS.K., ParkJ.S.Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin.Perit Dial Int.1997; 17: 157–61.
47.
HoeschenR.J.Oxidative stress and cardiovascular disease.Can J Cardiol.1997; 13: 1021–5.
48.
GeyK.F., BurbacherG.B., StahelinS.Plasma levels of antioxidant vitamins in relation to ischemic heart disease and cancer.Clin Nutr.1987; 45: 1368–77.
49.
RimmE.M., StampferM.J., AscherioA., GiovannucciE., ColditzG.A., WillettW.C.Dietary intake and risk of coronary heart disease among men.N Engl J Med.1993; 328: 1450–6.
50.
BeckerB.N., HemmelfarbJ., HenrichW.L., HakimR.M.Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors.J Am Sac Nephrol.1997; 8: 475–86.
51.
FoleyR.N., ParfreyP.S., HarnettJ.D., KentG.M., MurrayD.C., BarreP.E.Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease.J Am Soc Nephrol.1996; 7: 728–36.
52.
BlockG.A., Hulbert-ShearonT.E., LevinN.W., PortF.K.Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study.Am J Kidney Dis.1998; 31: 607–17.
53.
BlakeP.G.What is the problem with high transport ers?Perit Dial Int.1997; 17: 317–20.
